Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up

Carolyn T. Bramante, John B. Buse, David Liebovitz, Jacinda M. Nicklas, Michael A. Puskarich, Ken Cohen, Hrishikesh Belani, Blake Anderson, Jared D. Huling, Christopher J. Tignanelli, Jennifer L. Thompson, Matthew F Pullen, Lianne Siegel, Jennifer Proper, David J. Odde, Nichole R. Klatt, Nancy E. Sherwood, Sarah Lindberg, Esteban Lemus Wirtz, Amy B. Karger, Kenny Beckman, Spencer M Erickson, Sarah L. Fenno, Katrina M Hartman, Michael Rose, Barkha Patel, Gwendolyn Griffiths, Neeta Bhat, Thomas A. Murray, David R. BoulwaremedRxiv 2022 · DOI

TL;DR

In a large-scale, quadruple-blinded Phase 3 trial, researchers found that a two-week course of the common diabetes drug metformin reduced the risk of developing Long Covid by 42%. In contrast, ivermectin and fluvoxamine showed no significant effect on preventing the condition over a 10-month follow-up period.

What Problem Does This Paper Address?

While vaccines and antivirals have reduced the severity of acute COVID-19, "Long Covid" (Post-Acute Sequelae of SARS-CoV-2) remains a massive public health challenge, affecting millions with symptoms that can prevent work and daily activities.

There is a critical gap in the clinical toolkit: we lack proven, widely available, and inexpensive outpatient treatments that can be administered during the acute phase of infection to prevent the long-term development of the disease. The authors of the COVID-OUT trial sought to determine if three existing oral medications—metformin, ivermectin, and fluvoxamine—could fill this gap.

Methods

The researchers conducted a decentralized, multi-site, phase 3 randomized controlled trial (NCT04510194). Key features of the methodology include:

  • Factorial Design: A 2x3 factorial assignment was used to efficiently test three drugs simultaneously while sharing placebo controls.
  • Quadruple-Blinded: Participants, care providers, investigators, and outcome assessors were all blinded to treatment allocation.
  • Dosing Regimen:
    • Metformin: Titrated over 6 days to 1,500mg/day for 14 days total.
  • Ivermectin: 430mcg/kg/day for 3 days.
  • Fluvoxamine: 50mg twice daily for 14 days.
  • Endpoint: The primary outcome of the original trial was acute severe Covid. This paper focuses on a pre-specified secondary outcome: a medical-provider diagnosis of Long Covid reported by the participant through day 300.

Datasets

The "dataset" for this study consisted of 1,125 adults in the US, aged 30 to 85.

  • Inclusion Criteria: Participants were required to have a BMI ≥ 25 kg/m² (overweight or obesity), fewer than 7 days of symptoms, and a documented infection within 3 days of enrollment.
  • Demographics: The cohort was 56% female (7% of whom were pregnant) and 82.8% white, with a median BMI of 29.8 kg/m².
  • Vaccination: 55% of the cohort had received a primary vaccination series before enrollment.

Key Insights and Ideas

  • Metformin’s "Off-Label" Potential: While primarily a glucose-lowering drug, metformin has known anti-inflammatory properties. More interestingly, in silico and in vitro models suggest it can inhibit SARS-CoV-2 protein translation by suppressing the mTor pathway.
  • Early Intervention is Key: The trial enrolled patients very early in their infection (within 3 days of a positive test). This suggests that preventing the "inflammatory cascade" or reducing viral replication early on is crucial for preventing long-term sequelae.
  • Consistency Across Variants: The benefit of metformin was consistent across different viral variants (Alpha, Delta, and Omicron) and regardless of whether the participant was vaccinated.
  • Failure of Other Candidates: Despite significant public interest, neither ivermectin nor fluvoxamine showed any preventative benefit for Long Covid in this high-quality trial setting.

Key Results

  • Metformin Success: Only 6.3% of participants in the metformin group received a Long Covid diagnosis, compared to 10.6% in the blinded control group.
  • Hazard Ratio: The Hazard Ratio (HR) for metformin was 0.58 (95% CI 0.38 to 0.88), representing a 42% relative reduction in incidence.
  • Ivermectin/Fluvoxamine Results:
    • Ivermectin HR: 0.99 (no effect).
  • Fluvoxamine HR: 1.36 (statistically insignificant, but trended toward higher incidence).
  • P-Value: The p-value for metformin was 0.009, which remains significant even after Bonferroni correction for multiple testing.

Limitations and Future Work

  • Cohort Specificity: The trial specifically targeted adults with overweight or obesity (BMI ≥ 25) and those over age 30. It is unclear if these results generalize to younger, lower-BMI populations.
  • Secondary Outcome: Long Covid was a secondary endpoint, not the primary one. While the results are statistically robust, primary endpoints are generally considered the "gold standard" for clinical proof.
  • Diagnosis Method: The study relied on participant-reported medical-provider diagnoses. While this reflects real-world clinical practice, it is subject to the evolving definition of Long Covid.
  • Future Directions: The authors suggest future research should investigate optimal dosing, whether extended-release metformin is equally effective, and if there is synergy when metformin is combined with other antivirals like Paxlovid (nirmatrelvir).

Summary updated

Abstract

There was a 42% relative decrease in the incidence of Long Covid in the metformin group compared to its blinded control in a secondary outcome of this randomized phase 3 trial.
BibTeX
@misc{bramante2022outpatient,
  author = {Carolyn T. Bramante and John B. Buse and David Liebovitz and Jacinda M. Nicklas and Michael A. Puskarich and Ken Cohen and Hrishikesh Belani and Blake Anderson and Jared D. Huling and Christopher J. Tignanelli and Jennifer L. Thompson and Matthew F Pullen and Lianne Siegel and Jennifer Proper and David J. Odde and Nichole R. Klatt and Nancy E. Sherwood and Sarah Lindberg and Esteban Lemus Wirtz and Amy B. Karger and Kenny Beckman and Spencer M Erickson and Sarah L. Fenno and Katrina M Hartman and Michael Rose and Barkha Patel and Gwendolyn Griffiths and Neeta Bhat and Thomas A. Murray and David R. Boulware},
  title = {{Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up}},
  year = {2022},
  doi = {10.1101/2022.12.21.22283753},
  howpublished = {medRxiv},
}
Figure